{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-001543","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2026-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.961331+00:00","generated_at":"2026-05-16T09:31:15.426711+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aytu BioPharma launches EXXUA for MDD; reports $32.6M cash, reduced launch budget to $6-8M","bullets":["EXXUA (gepirone) is first FDA-approved 5HT1a agonist for MDD; full commercial launch underway after Dec 15, 2025 initial availability.","Cash $32.6M as of 9/30/25; TTM adjusted EBITDA $6.7M; launch budget reduced from $10M to $6-8M.","Commercialization deal with Fabre-Kramer: $3M upfront, 28% base royalty plus 3% on COGS, milestones starting at $100M net sales.","Pivotal trials showed significant HAM-D17 improvement vs placebo (P=0.018 and P=0.032); no sexual dysfunction or weight gain warning.","Targeting 5,500 high-value psychiatry prescribers; 40+ person sales force; virtual team to deliver 20,000 contacts in launch phase."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-001543","json":"https://secwatch.observer/filing/0001437749-26-001543.json","markdown":"https://secwatch.observer/filing/0001437749-26-001543.md","text":"https://secwatch.observer/filing/0001437749-26-001543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926001543/0001437749-26-001543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926001543/aytu20260118_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:31:15.426711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}